ArticleThe international journal of cardiovascular imaging2025
Myocardial fibrosis in severe asymptomatic versus symptomatic aortic stenosis: A cardiac magnetic resonance cross-sectional study.
Article in The international journal of cardiovascular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose The degree of myocardial fibrosis may guide the timing of aortic valve replacement in patients with severe asymptomatic aortic valve stenosis (AS). We aimed to examine the prevalence and degree of myocardial fibrosis in severe asymptomatic AS compared with severe symptomatic AS. Methods We prospectively included 42 patients with severe asymptomatic AS and 80 patients with severe symptomatic AS, all with a left ventricular ejection fraction ≥ 50% and no ischemic heart disease. All patients underwent a standard cardiac magnetic resonance examination, including native T1 mapping. Gadolinium contrast was administered to evaluate extracellular volume fraction (ECV%) and late gadolinium enhancement (LGE). Results There were no differences in myocardial fibrosis markers when comparing symptomatic with asymptomatic patients and adjusting for sex, age, and aortic peak velocity, including native T1 (mean difference [MD] -1 ms; 95% confidence interval [CI] -11 to 10; p = 0.90), ECV% (MD 0.2%; 95% CI -1 to 1; p = 0.65), LGE prevalence (odd ratio [OR] 1.2; 95% CI 0.4 to 3.3; p = 0.72), and a combined binary high- or low-grade fibrosis parameter (OR 1.1; 95% CI 0.3 to 4.0; p = 0.94). Conclusion Patients with severe asymptomatic AS exhibited similar severity of myocardial fibrosis markers as those with severe symptomatic AS, suggesting that substantial myocardial damage precedes symptom development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.